These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 5131188)

  • 1. [Study of hepatic function before and after administration of therapeutic doses of clofibrate].
    Dal Monte PR; Menghi B; Cremonini R; Sarti F; Toscano S
    Minerva Med; 1971 Dec; 62(97):4815-29. PubMed ID: 5131188
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical, biochemical and pathological studies of long term "clofibrate" therapy.
    el-Mehairy MM; Attia O; Nabih AE; Nassar I; Ibrahim WN
    J Trop Med Hyg; 1970 Jul; 73(7):177-81. PubMed ID: 5470220
    [No Abstract]   [Full Text] [Related]  

  • 3. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
    Laurin J; Lindor KD; Crippin JS; Gossard A; Gores GJ; Ludwig J; Rakela J; McGill DB
    Hepatology; 1996 Jun; 23(6):1464-7. PubMed ID: 8675165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of clofibrate in hypercholesterinemic rabbits and in arteriosclerotic subjects-modifications of platelet aggregation and fibrinolysis as related to lipidic fractions.
    Baldoni F; Egge H; Giarola P; Müller H; Cuttin S; Gibelli A; Zilliken F; de Nicola P
    New Istanbul Contrib Clin Sci; 1972 Dec; 10(3):135-8. PubMed ID: 4670445
    [No Abstract]   [Full Text] [Related]  

  • 5. [Study of clofibrate. The opinion of Prof. D. Kritchevsky].
    Fabbrocini V
    Minerva Cardioangiol; 1980 Nov; 28(11):759-60. PubMed ID: 7231692
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapeutic results with combination of pyridinolcarbamate and clofibrate in atherosclerotic patients].
    Valiensi M; Riboli E; Lombardi M
    Minerva Cardioangiol; 1976 Feb; 24(2):148-54. PubMed ID: 1256654
    [No Abstract]   [Full Text] [Related]  

  • 7. [Real or alleged risks of clofibrate derivatives and certain risks of their prohibition].
    de Gennes JL
    Nouv Presse Med; 1979 Mar; 8(15):1223-5. PubMed ID: 375186
    [No Abstract]   [Full Text] [Related]  

  • 8. [Comparative effect of probucol and clofibrate in patients with primary hypercholesterolemia].
    Pasquali R; Melchionda N; Parenti M; Cavazzini MG; Biso P; Baraldi G; Sorrenti G; De Benedittis G; Labò G
    Clin Ter; 1982 Dec; 103(5):509-20. PubMed ID: 7160143
    [No Abstract]   [Full Text] [Related]  

  • 9. [The importance of pyridinolcarbamate and clofibrate association in the treatment of arteriosclerosis].
    Pola P
    Minerva Cardioangiol; 1975 Apr; 23(4):261-9. PubMed ID: 1095958
    [No Abstract]   [Full Text] [Related]  

  • 10. [The importance of pyridinolcarbamate and clofibrate association in the treatment of arteriosclerosis].
    Pola P
    J Pharm Sci; 1975 Jan; 64(1):261-9. PubMed ID: 1094102
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate].
    Mertz DP
    Fortschr Med; 1980 Dec; 98(45):1761-6. PubMed ID: 7461569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of clofibrate on serum lipid pattern in patients with arteriosclerosis].
    Markiewicz K; Walasek L; Pelka W; Lutz W
    Pol Tyg Lek; 1973 Jul; 28(30):1144-7. PubMed ID: 4732710
    [No Abstract]   [Full Text] [Related]  

  • 13. [Behavior of electrocardiographic and rheographic tracings in atherosclerotic subjects treated with clofibrate].
    Furitano G; Aguglia V
    Boll Soc Ital Cardiol; 1973; 18(4):357-60. PubMed ID: 4807074
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical, biochemical and histological study of the evolutive forms of acute hepatitis. Apropos of 53 cases].
    Dal Monte PR; Fiore E; Cremonini R; Montroni M
    G Clin Med; 1969 Mar; 50(3):185-221. PubMed ID: 5355945
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effects of clofibrate, Isopharm, on fat tolerance in atherosclerotic patients].
    Passowicz L
    Pol Tyg Lek; 1972 Jul; 27(30):1163-6. PubMed ID: 5073024
    [No Abstract]   [Full Text] [Related]  

  • 16. [The clofibrate-dipyridamole combination in the prevention and therapy of arteriosclerotic vascular disease and its complications].
    Cucinotta D; Ferretti PG; Daccò L; Mazzera F
    G Clin Med; 1977; 58(11-12):475-86. PubMed ID: 608558
    [No Abstract]   [Full Text] [Related]  

  • 17. [Results and prospects of the use of drugs acting on serum lipoproteins in atherosclerosis].
    Fasoli A
    Minerva Med; 1971 Sep; 62(72):3458-65. PubMed ID: 5097217
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of hyperlipidemias. Value of a new hypolipidemic drug clofibride, (M-G. 46)].
    Leutenegger M; Choisy H; Caron J; Paris H
    Therapie; 1974; 29(4):599-610. PubMed ID: 4439371
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical and therapeutic evaluation of simfibrate compared toclofibrate in atherosclerotic patients].
    De Rosa G; Savi L; De Rosa E; Pola P; Boni P
    Clin Ter; 1979 Feb; 88(3):267-79. PubMed ID: 376218
    [No Abstract]   [Full Text] [Related]  

  • 20. [Papaverine and liver damage. Investigation of liver function in 25 patients treated with papaverine intra-arterially].
    Westheim A
    Tidsskr Nor Laegeforen; 1972 Oct; 92(30):2020-2. PubMed ID: 4634644
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.